Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801686 | 0.70 | GRM4 (0.35) | GRM4 | |
| SCHEMBL2132478 | 0.70 | MAP2K4 (0.43) | MAPK1FFAR1 | |
| SCHEMBL2132482 | 0.70 | MAP2K4 (0.43) | MAPK1FFAR1 | |
| SCHEMBL325244 | 0.69 | HCAR2 (0.36) | GRM4 | |
| SCHEMBL31076243 | 0.67 | FFAR1 (0.46) | FFAR1 | |
| SCHEMBL32677636 | 0.67 | FFAR1 (0.46) | FFAR1 | |
| SCHEMBL31076269 | 0.66 | FFAR1 (0.38) | FFAR1 | |
| SCHEMBL24738081 | 0.66 | MAP2K4 (0.39) | FFAR1 | |
| SCHEMBL5084942 | 0.65 | RPS6KB1 (0.38) | GRM4 | |
| SCHEMBL30343654 | 0.65 | RPS6KB1 (0.38) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-1689751-B1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| US-7569572-B2 | Pyrazolo[4,3-D]pyrimidines | PFIZER INC (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1742950-B1 | PYRAZOLO[4,3-D] PYRIMIDINES | PFIZER LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20080293697-A1 | Pyrazolo[4,3-D]Pyrimidines | BELL ANDREW SIMON | 2008-11-27 | — | — | US | disclosed |
| EP-1689752-B1 | PYRAZOLOPYRIMIDINES | PFIZER LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070105877-A1 | Pyrazolopyrimidines | PFIZER INC | 2007-05-10 | — | — | US | disclosed |
| EP-1689752-A1 | PYRAZOLOPYRIMIDINES | Pfizer Limited (GB) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689751-A1 | 5,7-DIAMINOPYRAZOLO¬4,3-D|PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | Pfizer Limited (GB) | 2006-08-16 | — | — | EP | disclosed |
| US-20050245544-A1 | Novel pharmaceuticals | AMPLIFIED PROTEOMICS INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005049616-A1 | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049617-A1 | PYRAZOLOPYRIMIDINES | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293697-A1 | Pyrazolo[4,3-D]Pyrimidines | DPYD, TYMS, TYMP | CYP4F2 121/4885CYP4A11 336/4885GRM4 2401/4885 |
| US-20050043325-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | CYP4F2 127/4885CYP4A11 66/4885GRM4 4197/4885 |
| US-20050245544-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | CYP4F2 127/4885CYP4A11 66/4885GRM4 4197/4885 |
| US-20070105877-A1 | Pyrazolopyrimidines | DPYD, CYP2D6, TPMT | CYP4F2 21/4885CYP4A11 261/4885GRM4 3307/4885 |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | ABCB11, PCSK9, SLC10A1 | CYP4F2 127/4885CYP4A11 66/4885GRM4 4197/4885 |
| US-20090247539-A1 | Novel Pharmaceuticals | ABCB11, PCSK9, SLC10A1 | CYP4F2 127/4885CYP4A11 66/4885GRM4 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.